Twinject 0.15 Patent Expiration

Twinject 0.15 is a drug owned by Impax Laboratories Llc. It is protected by 2 US drug patents filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 04, 2025. Details of Twinject 0.15's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7621891 Method and apparatus for delivering epinephrine
Feb, 2025

(a month from now)

Active
US7297136 Medicine injection devices and methods
Jan, 2025

(a month from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Twinject 0.15's patents.

Given below is the list of recent legal activities going on the following patents of Twinject 0.15.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 18 Dec, 2020 US7621891
Payment of Maintenance Fee, 12th Year, Large Entity 17 May, 2019 US7297136
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 31 May, 2011 US7297136
Change in Power of Attorney (May Include Associate POA) 20 Apr, 2010 US7621891
Change in Power of Attorney (May Include Associate POA) 20 Apr, 2010 US7297136
Correspondence Address Change 16 Apr, 2010 US7297136
Correspondence Address Change 16 Apr, 2010 US7621891
Patent Issue Date Used in PTA Calculation 24 Nov, 2009 US7621891
Recordation of Patent Grant Mailed 24 Nov, 2009 US7621891
Issue Notification Mailed 04 Nov, 2009 US7621891

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Twinject 0.15 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Twinject 0.15's family patents as well as insights into ongoing legal events on those patents.

Twinject 0.15's Family Patents

Twinject 0.15 has patent protection in a total of 15 countries. It's US patent count contributes only to 34.0% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Twinject 0.15.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Twinject 0.15's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 04, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Twinject 0.15 Generic API suppliers:

Epinephrine is the generic name for the brand Twinject 0.15. 4 different companies have already filed for the generic of Twinject 0.15, with Am Regent having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Twinject 0.15's generic

Alternative Brands for Twinject 0.15

There are several other brand drugs using the same active ingredient (Epinephrine) as Twinject 0.15. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.


Apart from brand drugs containing the same ingredient, some generics have also been filed for Epinephrine, Twinject 0.15's active ingredient. Check the complete list of approved generic manufacturers for Twinject 0.15





About Twinject 0.15

Twinject 0.15 is a drug owned by Impax Laboratories Llc. Twinject 0.15 uses Epinephrine as an active ingredient. Twinject 0.15 was launched by Impax in 2009.

Approval Date:

Twinject 0.15 was approved by FDA for market use on 25 November, 2009.

Active Ingredient:

Twinject 0.15 uses Epinephrine as the active ingredient. Check out other Drugs and Companies using Epinephrine ingredient

Dosage:

Twinject 0.15 is available in injectable form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.15MG/DELIVERY INJECTABLE Discontinued INTRAMUSCULAR, SUBCUTANEOUS